Burn ointment

FIELD: medicine.

SUBSTANCE: ointment contains biologically active substances which are Apis mellifera in an amount of 21-23 wt %, St. John's wort oil in an amount of 12-14 wt %, propolis in an amount of 10-12 wt % and wax in an amount of 7-9 wt %, as well as Vaselin and lanolin as the ointment base.

EFFECT: invention accelerates cell regeneration processes considerably due to a synergetic action of the ingredients.

7 ex

 

The invention relates to medicine and veterinary medicine, and in particular to compositions for the treatment of burns.

Known biological ointment for the treatment of eye burns, made on the basis of specially treated human fat (humanely) and contains b vitamins and sulfacetamide-sodium (Philemenof "the Use of a new drug blood biological ointment in treatment of eye burns / journal of ophthalmology, 1963. - P.56-59). Biological ointment helps to regenerate damaged tissue in burns, and non-penetrating injuries of the cornea. The disadvantage of the drug is not sufficiently high wound-healing effect, and therefore the longer the treatment time.

Also known eye ointment, containing a biologically active substance isolated from the umbilical cord of a man of high molecular weight hyaluronic acid (0.3-0.5 g) and ointment base (petrolatum - lanolin in the ratio 6:4) - the rest (Patent RU №217336). The disadvantage of this method is of limited use of the drug - it is effective only if multiple applications (3-4 times daily) and long term wound healing eyes - 30 days. In addition, the drug is tested only if the chemical burn of the cornea, and in other types of burn lesions no information. Getting drug is hampered by the complexity of technology provide the basics to the CSO component hyaluronic acid from umbilical cord of a person that is not readily available and technically difficult.

Meanwhile, from the field of jainology it is known that currently the development of new methods of treatment of burns and wounds use: polymeric coatings. To ensure adequate therapeutic effect of coverage must meet certain special requirements, which include minimum trauma to the wound surface when applying and removing dressings, they should absorb the liquid that accumulates on the surface of the wound, to protect from contamination. Coatings based on chitin compounds occupy a special place in this list, and the first attempts to use Chudinov and chitosan for healing of wounds, including burns, were described in the mid 1970s (R.A.A. Muzzarelli. Chitin. - Oxford: Bugamon Press, 1977). It is established that these compounds possess hepatoprotective, antiulcer, antioxidant, immunostimulant, antioxidant, antibacterial, normalizing autosecretary bowel and regenerating (stimulating the healing of wounds, ulcers and burns) properties. It is established that the coating burns drug "Hitoff", which includes chitosan and a water extract of Siberian fir "Ausib", well protects affected by the burn surface, has an analgesic effect, schraut regeneration and the formation of the epidermal layer (Aiello and other Different types of chitosan in veterinary medicine and animal husbandry / agricultural Russia. - 2004. No. 5. - P.8-11).

However, the technology of production of chitin and chitosan involves serious technical difficulties because it involves deproteinizovana and diallylamine technical raw materials (shells of crabs, molluscs) with concentrated alkalis and acids at high temperatures (of the order of 130-150°C), and obtaining chitosan films based on polymers even more difficult, expensive and not readily available.

Meanwhile, it is known that the number of bee products (propolis, wax, honey and dead bees), can be effectively used without special treatment as one of the main components burn ointments.

Closest to the patentable invention is an emulsion ointment against burns (As the USSR # 68832, 1977). Specified as the prototype drug is intended for treatment of burns and contains (wt.%): lanolin - 5-10; naphthalene - 20-30; neutral lard - 10; refined technical fat - 40-16; turpentine - 3-10; beeswax with traces of honey - 10, meticillin - 3; fish oil - 5-7; complex of vitamins A+D+C - 1,0; metafun (bactericide) - 0,25; cholesterol - 1.0; lecithin is 1.75. However, the composition of the ointment is very complex and it contains antiseptics - turpentine, methyl salicylate, metapan, which, as shown by the last toksikol the policy studies unsafe for the Central nervous system, blood-forming organs and gastrointestinal tract, and thereby toxic effect on the affected burn the body, which contains in excess of burn toxins.

Object of the present invention is to improve wound healing of burns effect with simultaneous simplification of the composition, with the exception of drug toxic components and reduction of terms of treatment of patients.

This task is achieved by the fact that for the healing of burn wounds in the composition of the ointment contains active substances that enhance the regeneration of damaged tissue in burns and suppression of pathogenic microorganisms in the injured with burns and infected wounds.

The inventive preparation is an ointment containing biologically active substances and ointment base, characterized in that the biologically active substances using the dead bees, trapping oil, propolis and wax, as well as ointment bases - petrolatum and lanolin in the following ratio, wt.%: the dead bees - 21-23, trapping oil - 12-14; propolis - 10-12; wax - 7-9; ointment base (petrolatum-lanolin 1:1) - else.

Ointment for the treatment of burns based on chitosan-containing substance - bee Podmore (STM), trapping oil, propolis and wax greatly accelerates the processes to emochnoy regeneration thanks to film-forming, anti-inflammatory antibacterial, antioxidant, antitoxic, anti-ulcer and wound healing synergistic action of the components.

At the first stage of cooking techniques ointments are training the main raw materials for industry - bee Podmore. For this purpose collect fresh dead bees free of mold and signs of decay. The raw material is sieved through a sieve with large cells, to separate it from small debris. After that, the sample is dried in the oven, in the oven at a temperature of +40...45°C or above Central heater. The dry material is subjected to homogenization in a ball mill or coffee grinder. The degree of dispersion control microscopically, which should be within 60-90 microns. The resulting powder was used as one of the main components of burn ointment.

For the preparation of the second medical component - trapping oil, take 20 grams (3 tablespoons) of fresh leaves of St. John's wort, pour 200 g of sunflower oil. Insist 2 weeks in a dark place at room temperature, at times, shake, then strain.

The technological process of preparation of ointments as follows. In a reactor equipped with a combination stirrer, jacketed for heating (cooling) and external homogenizer, vesamenu basis (petrolatum-lanolin). The process is at a temperature of 50-55°C. In the resulting pasty mass ointment bases with continuous homogenization contribute trapping oil, then, as the dissolution and formation of a homogeneous mass, contribute consistently wax, propolis and powder bee Podmore.

The degree of homogenization is assessed visually and microscopically. The ointment should be visually homogeneous with an average particle size of 60 to 90 μm. Packing ointment is made on the packing machine in plastic tubes 50-100,

Production safety is discussed in the relevant sections of the regulations and safety instructions. To ensure sanitary standards of the premises where produced, Packed and packaged ointment, equipped with supply and exhaust ventilation, air conditioning and germicidal UV lamps. According to the degree of fire and explosion hazard production ointment belongs to the category "B"on sanitary design standards - non-toxic, according to the rules for electrical installation - non-explosive. By-products, waste water and air emissions in the production of ointments are missing.

For experimental verification of the claimed burn ointments were prepared ointments containing various amounts of bee Podmore(19%; 21%; 23%; 25%; 27%), trapping oil(8%; 10%; 12%; 14%; 16%), propolis (6%; 8%; 10; 12%; 14%) and wax(5%; 7%; 9%; 11%; 13%).

Example 1. Preparation of ointments (per 1.00 wt.%). In aseptic conditions when heated to 50-55°C. and stirring is mixed with 25 wt.% vaseline and 25 wt.% lanolin, in this mixture contribute 8 wt.% trapping oil and after complete homogenization alternate as complete dissolution and homogenization - wax (5 wt%), propolis (6 wt%), and then powder bee Podmore (19 wt%). The mixture is stirred with simultaneous homogenization.

Example 2. Under the conditions of example 1 take 21 wt.% bee Podmore, 10 wt:% trapping oil, 8 wt.% propolis and 7 wt.% the wax.

Example 3. Under the conditions of example 1 take 23 wt.% bee Podmore, 12 wt.% trapping oil, 10 wt.% propolis and 9 wt.% the wax.

Example 4. Under the conditions of example 1 take a 25 wt.% bee Podmore, 14 wt.% trapping oil, 12 wt.% propolis and 11 wt.% the wax.

Example 5. Under the conditions of example 1 taken 27 wt.% bee Podmore, 16 wt.% trapping oil, 14 wt.% propolis and 13 wt.% the wax.

When applying ointment with content of 19 wt.% bee Podmore, 8-10 wt.% trapping oil, 6-8 wt.% propolis and 5 wt.% wax there is insufficient wound healing effect. Ointments with the content of 21-23 wt.% bee Podmore, 12-14 wt.% trapping oil, 10-12 wt.% propolis and 7-9 wt.% wax has good wounds the healing activity. When increasing the percentage of dead bees to 27 wt.%, trapping oil to 16 wt.%, propolis to 14 wt.% and wax - up to 13 wt.% in ointment wound healing effect was not increased. Optimal was ointments containing 21-23 wt.% dead bees, 12-14 wt.% trapping oil, 10-12 wt.% propolis and 7-9 wt.% the wax.

From experimental studies it can be concluded that burns ointment prepared from components: dead bees - 2.1-23 g, trapping oil - 12-14 g propolis - 10-12 g, wax - 7-9 g ointment base - 58-42 g meets the requirements of Pharmacopia X: sterile, biologically active substances are easily mixed to a homogeneous mass, therapeutic effect in non-toxic and not irritating skin doses. Ready ointment is a viscous mass of yellow color with a characteristic smell uniform consistency. The drug is available for use in domestic and industrial environments.

The proposed burn ointment tested in experiments on rabbits. Therapeutic efficacy was evaluated by the following criteria: the timing of the reversal and extinction phenomena of irritation, swelling, purulent-necrotic lesions, the timing of the complete epithelialization tissue.

Example 1. Test the effectiveness of the ointment if the burn is mild. In the experiments used 6 Krolik is, divided into 2 groups. Modeling thermal burn was performed using light flashes six halogen lamps located at a distance of 10 mm from shaved 10% of the surface area of the skin of animals. At 24 h after injury, the affected area of the skin of rabbits 1st group were treated emulsion ointment against burns (known product). The affected area of the animals of the 2nd group smeared with ointment against burns-based bee Podmore, trapping oil, propolis and wax (proposed). It is established that the burn injury in animals of the 1st group was accompanied by a strong erythema of the skin, diffuse edema and complete wound healing occurred only on day 13-15 experience. Animals of the 2nd group of burn injury after applying the proposed ointment accompanied by slight erythema, slight edema, which disappeared to 5-6 days after injury.

Example 2. Test the effectiveness of the ointment if the burn is severe (III) degree. Simulation of severe burn was carried out by burning 10% of the surface of the body of hot metal plasticity. After 24 h after application of burn injury, the affected area of the skin of rabbits 1st group were treated emulsion ointment of known composition. For the treatment of burn injuries rabbits 2nd group used the proposed ointment-based bee Podmore and C is arabinose oil. The results of dynamic observations showed that the animals of the 1st group of wound process, despite the application of emulsion ointments against burns, was accompanied by the development of diffuse edema, the formation of vesicles and erosions in the center. Wound healing with scarring occurred at 19-21 days after injury. Animals of the 2nd group after applying the proposed ointment observed that the wound surface was covered with a film formed due to the presence in the composition of ointments chitosan-containing component - bee Podmore, that prevented the wound from microbial contamination, absorb wound exudate. On the third day observed reduction of the area of the lesion, resorption of edema, absence of purulent-necrotic process and scars. Wound healing occurred on 12-13 days after injury.

Ointment for the treatment of burns, containing biologically active substances and ointment base, characterized in that it as biologically active substances contains dead bees, trapping oil, propolis and wax, as well as ointment bases contains petrolatum and lanolin in the following ratio, wt.%: the dead bees - 21-23; trapping oil - 12-14; propolis - 10-12; wax - 7-9; ointment base (petrolatum-lanolin 1:1) - the rest.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves coating a keratoma surface with a mixture of meadow saffron tincture 1 table spoon and Phellinus tuberculosus tincture 3-4 drops. The mixture is applied once a day on the keratoma and a skin area 1.5-2.0 mm from the keratoma border. The mixture is applied by a thin brush, first with a prime layer and with a second layer after drying.

EFFECT: minimally painful keratoma removal.

3 ex

FIELD: medicine.

SUBSTANCE: material consists of several layers: an inner layer is made from chitosan nanofibres/superfine fibres, and an outside layer are used as an electrical forming substrate and exercise the protective function. The chitosan layer is made from herbal or mixed herbal and animal chitosan and can contain antibiotic. The multilayer material can contain at least one more layer of biopolymer nanofibres/superfine fibres electroformed of cellulose diacetate or gelatin. The three-layer material with the chitosan layer of the nanofibres/superfine fibres is applicable for local wound and burn healing.

EFFECT: material resistance to mechanical stress.

15 cl, 4 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatology and may be used for stimulating repair of wounds of various geneses. For this purpose, wound cleansing is followed by daily dressings with dihydroquercetin powder applied on a wound surface at the bacterial content no more than 103-4 m.c. per 1 cm2 as a layer of 1-2 mm until wound self-epithelisation, before or after autodermoplasty with a free split-skin flap. That is combined with prescribing the biologically active additive Laviocard+ orally 1 capsule 2 times a day with food for 21 day.

EFFECT: method provides correcting abnormal lipid peroxidation and activating antioxidant protection in local and systemic homeostasis by stimulating and reducing a repair length.

2 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention can be used for treating degree III-IV radiation injuries on radiation fields following neutron therapy in patients suffering from local recurrent breast cancer (BC). That is ensured by wound irrigation with ozonised distilled water with ozone concentration of 10,000 mcg/l; a skin ulcerous defect is processed in a vacuum container for 10-15 minutes with gaseous ozone with the concentration of 10,000 mcg/l. That is followed by ozonised air applications with the parameters of: peroxide number - 18%, acid number - 71 mg CFU/g on the skin ulcerous defect once or twice a day for 10-15 days every 5-7 days for 2-3 courses.

EFFECT: ulcer detersion from purulent deposits, active regeneration and the skin ulcerous defect healing.

6 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and may be used for treating an individual suffering from a persistent, sluggish, partially healing, open or chronic wound. That is ensured by administering anti-connexin 43 polynucleotide approximately 0.001 to approximately 1 mg/kg of body weight into the wound of the individual in a pharmaceutically acceptable carrier. Stimulating and improving wound healing, improving wound healing rate in a diabetic patient and an individual suffering from a chronic skin wound is also suggested. Kits and finished products containing Pluronic F-127 and anti-connexin 43 polynucleotide presented by SEQ ID NO: 1 for wound healing.

EFFECT: group of inventions provides wound healing, relieved inflammation within the persistent wound, as well as minimised cicatrisation.

129 cl, 4 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula (1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.

EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.

26 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.

EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.

1 tbl

FIELD: chemistry.

SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.

1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method.

EFFECT: inventions make it possible to increase step-by-step output of the hepatocyte growth factor, with the hepatocyte growth factor being concentrated in eluate in the presence of AT-III.

26 cl, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues.

EFFECT: pharmaceutical composition is effective for dehydration, atrophy and removal of abnormal tissues in treating haemorrhoids, haemangiomas, varicose veins, burns, bleeding traumatic wounds, local wounds caused by chemicals or microorganisms.

9 cl, 12 dwg, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition can additionally contain ethylenediaminotetraacetic acid, polyvinyl pyrrolidone, polyvinyl alcohol, a preserving agent specified in a group: Nipagin, Nipasol, benzoic acid, sodium benzoate, sorbic acid, benzalkonium chloride. As a body-forming base, the composition can contain distilled water, polyethylene oxide 400, polyethylene oxide 4000, polyethylene glycol, propylene glycol, a phosphate buffer, a borate buffer, an acetate-borate buffer depending on a dosage form.

EFFECT: high therapeutic effectiveness, prolonged corneal contact of the preparation which reduces the number of instillations, avoids a risk of side effects and provides good tolerance.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to the veterinary science and is applicable for treating bovine digital dermatitis. A method involves applying a preparation in the form of an ointment of the following formulation, wt %: veterinary copper sulphate 35-45, zinc oxide 9-11, an ointment base - the rest. The preparation is made by mixing the ingredients until smooth. The preparation is applied on the involved regions 1-2 times with or without a protective dressing.

EFFECT: method is effective in treating bovine digital dermatitis.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: topical gel composition for treating erythema or a related symptom contains brimonidine 0.4 wt % to 0.6 wt %, preferentially in the form of brimonidine tartrate, a gelatinising agent, and at least one polyol. The topical application of the gel composition on the skin involved in erythema or having a manifestation of the related symptom has an effect on a serum or plasma profile of brimonidine with an average Cmax approximately 54±28 pcg/ml or less and an average AUC0-24h approximately 568±277 pcg·h/ml or less.

EFFECT: safe and effective treatment of erythema causing no inadequate drug-related side effects.

19 cl, 3 dwg, 5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to a composition containing encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters, or triterpene alcohol - betulin, which may be used in medicine for treating and preventing viral infections caused by DNA and RNA-containing viruses, such as influenza viruses, oncogenic viruses, herpes virus, herpes zoster virus, as well as infections caused by gram-positive and gram-negative bacteria: Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida, including multiresistant strains, as well as Actinomycetes and some pathogenic protozoa: Entamoeba histolytica, Trichomonas vaginalis. The invention presents the composition containing an active ingredient presented by 0.5 wt % of betulin or 0.5 wt % of encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters and others, and carriers presented by: β-cyclodextrins, fullerene, lecithins and polymers binding to the ingredients to form ingredient-carrier complexes, and excipients.

EFFECT: higher efficacy of using the composition.

3 cl

Wound-healing drug // 2517065

FIELD: chemistry.

SUBSTANCE: invention relates to a wound-healing drug which consists of stearic acid; castor oil; zinc stearate; 70% alcohol extract of a plant collection including oak tree bark, marigold flowers, wild chamomile flowers, nettle leaves, taken in ratio of 1:3:2:1, respectively; Na salts of fatty acids of wool fat; boric acid; vaseline; glycerine; triethanolamine; treated water; vegetable oil; Tipton weed extract; wild rose oil or sea buckthorn oil; 10% propolis oily solution; natural L-amino acid-peptide biocomplex obtained by extracting native paunch manure of ruminants with 2.0-3.0% NaCl solution; purified lanolin and derivatives thereof.

EFFECT: improved bactericidal, anti-inflammatory, regenerating, antioxidant and antimicrobial properties, drug does not have allergic action.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for treating an oral mucosal involvement accompanying lichen acuminatus. An adhesive ointment for treating the oral mucosal involvements accompanying lichen acuminatus containing sea buckthorn oil and 0.5% prednisolone ointment, socoseryl dental adhesive paste and vitamin A in the specific proportions.

EFFECT: ointment is effective for treating the oral mucosal involvements accompanying lichen acuminatus.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely an agent possessing anticoagulant activity. A method for preparing a dry fucus extract possessing anticoagulant action by the complex treatment of Fucus vesiculosus. The dry fucus extract possessing anticoagulant activity representing a polysaccharide complex containing fucoidan having the following composition: neutral monosaccharides - fucose, xylose, mannose, galacose, glucose, uronic acid; as well as polyphenols and sulphates in specific amount. The anticoagulant ointment containing the dry fucus extract.

EFFECT: agents described above possess pronounced anticoagulant action.

4 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmacy and concerns the development of an ointment containing mechanically activated amorphous or amorphous crystalline calcium gluconate, and may be used in the integrated treatment of skin diseases related to calcium deficiency, namely to the integrated treatment of dermatoses: psoriasis, atopic dermatitis, eczema and keratoderma. As an active ingredient, the ointment contains mechanically activated amorphous or amorphous crystalline calcium gluconate; an ointment base is Vaseline, glycerol, emulsifier No.1, Lutrol F 127 and purified water in the following proportions, wt %: mechanically activated amorphous or amorphous crystalline calcium gluconate-5.0; Vaselin-10.0; glycerol-10.0; emulsifier No.1-8.0; lutrol F 127-2.0 and purified water up to 100.0.

EFFECT: ointment possesses high therapeutic activity, provides the uniform release of the active ingredient that is mechanically activated amorphous or amorphous crystalline calcium gluconate, the manifested prolonged action and applicability by the patient.

4 ex

FIELD: medicine.

SUBSTANCE: invention represents a method for increasing biocidal and therapeutic action of a suspension-cream with linco-spectin consisting in detoxification and polymerisation of linco-spectin 100 g in water 300 ml by 0.15±0.05% glutaric aldehyde 0.15±0.05% alkyldimethyl benzylammonium chloride at 38-40°C for 2-3 days.

EFFECT: linco-spectin resistance to the enzymatic degradation of a microbial cell, lower toxicity, faster tissue regeneration and manifested biocidal action on the pathogenic bacteria, viruses, and moulds for 3 years.

5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of 2-nitroheterylthiocyanates, particularly 4-rhodano-5-nitropyrimidine and 2-rhodano-3-nitripyridine derivatives of general formula (I), optionally in crystalline form or in form of pharmaceutically acceptable addition salts thereof with acids or bases, having activity on fungal strains, fungal infection agents, for producing pharmaceutical compositions that are suitable for local application. The compounds are also active on strains that are resistant to existing drugs. In general formula (I) X=N or C-R3, R1 denotes a proton, a saturated or unsaturated linear alkoxy radical having 1-5 carbon atoms; a cycloalkyloxy radical having up to 6 carbon atoms; a saturated linear alkylmercapto radical having 1-3 carbon atoms; an amino radical having 1-10 carbon atoms, selected from a saturated or unsaturated linear mono- or dialkylamino radical or a cycloalkylamino radical, cyclic amino radical. Each of the cyclic groups can be substituted with 1-2 methyl groups, or a benzylamino group; R2 denotes a proton, a saturated or unsaturated linear alkyl radical having 1-5 carbon atoms, or a cyclic aliphatic radical having up to 6 carbon atoms, trifluoromethyl, styryl or methylmercapto group; R3 denotes a trifluoromethyl, formyl, acetyl, nitro, benzoyl, cyano group or an alkoxycarbonyl substitute having 1-3 carbon atoms in the alkoxy group.

EFFECT: improved properties of compounds.

5 cl, 3 tbl, 21 ex

FIELD: medicine.

SUBSTANCE: invention refers to biochemistry. What is involved is a qualitative assessment of the efficacy of oleic acid as an RNA carrier through biological membranes. The biological membrane is presented by soft sac cells of ripe pulp of honey pomelo of the genus Citrus. The RNA carrier is presented by oleic acid from the preparation Vitalang-2 in an amount of 10.8% and forming a complex with RNA. The preparation Vitalang-1 containing pure RNA is used as a reference. The pomelo cells are poured separately with aqueous solutions of the preparations Vitalang-1, Vitalang-2 and distilled water in an amount of 4.8 ml in each flask. They are incubated for 22 hours at room temperature. A spectrophotometer is used to measure optical density of the solutions versus distilled water with determining the RNA content in the pomelo cells and surrounding solution. Comparing the derived optical densities of the solutions provides stating the fact that Vitalang-2 penetrates through the biological membranes by 4.7-4.9 times more effectively than the preparation Vitalang-1. It is stated that absorption spectra of RNA recovered from the soft sacs are identical to those for the initial compounds.

EFFECT: invention enables assessing the efficacy of oleic acid used as the RNA carrier through the biological membranes.

1 ex

Up!